Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147
Kanyarat Thongheang1,2, Thanathat Pamonsupornwichit2, Kanokporn Sornsuwan2,3
1Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
Background:
Triple-negative breast cancer (TNBC) is an aggressive subtype with high metastatic potential, poor prognosis, and the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). The lack of these receptors limits the standard treatments, such as hormone therapies and HER2-targeted antibodies like trastuzumab. These challenges highlight the critical need for novel therapeutic strategies. CD147, a transmembrane glycoprotein overexpressed in TNBC, promotes tumor progression, metastasis, and chemoresistance, making it a promising therapeutic target. This study evaluates the antibody-dependent cellular cytotoxicity (ADCC) of HuM6-1B9, a humanized anti-CD147 antibody, against MDA-MB-231 cells, a TNBC model.
Methods:
CFSE-labelled MDA-MB-231 cells were co-cultured with PBMCs as effector cells (E:T ratio 80:1) in the presence of HuM6-1B9 and incubated for 4 h. Cells were then collected and stained with PI, and CFSE+/PI+ dead target cells were analyzed by flow cytometry.
Results:
Co-culturing MDA-MB-231 cells with peripheral blood mononuclear cells (PBMCs) in the presence of HuM6-1B9 demonstrated effective ADCC induction without direct cytotoxicity. HuM6-1B9 induced 54.01% cancer cell death via ADCC, significantly outperforming trastuzumab (26.14%) while sparing PBMCs.
Conclusion:
These findings support HuM6-1B9 as a prospective TNBC therapeutic and warrant further investigation into its clinical potential.
Insights
A new antibody, HuM6-1B9, shows promise for treating triple-negative breast cancer (TNBC). It effectively kills cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and may offer a better option than current therapies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Triple-negative breast cancer (TNBC) is aggressive, lacks standard treatment targets (ER, PR, HER2), and has a poor prognosis.
- CD147 is overexpressed in TNBC, driving tumor progression, metastasis, and chemoresistance, making it a key therapeutic target.
- Novel strategies are needed due to limitations of current therapies like hormone therapies and HER2-targeted antibodies.
Purpose of the Study:
- To evaluate the antibody-dependent cellular cytotoxicity (ADCC) of the humanized anti-CD147 antibody, HuM6-1B9.
- To assess the efficacy of HuM6-1B9 against MDA-MB-231 cells, a model for triple-negative breast cancer.
- To compare HuM6-1B9's ADCC activity with that of trastuzumab.
Main Methods:
- MDA-MB-231 cells were labeled with CFSE and co-cultured with peripheral blood mononuclear cells (PBMCs) as effector cells.
- The co-culture system utilized an effector-to-target cell ratio of 80:1 in the presence of HuM6-1B9.
- Cell death was analyzed via flow cytometry after staining with propidium iodide (PI) to identify dead target cells (CFSE+/PI+).
Main Results:
- HuM6-1B9 effectively induced ADCC against MDA-MB-231 cells without causing direct cytotoxicity.
- The anti-CD147 antibody HuM6-1B9 mediated 54.01% cancer cell death through ADCC.
- HuM6-1B9 demonstrated significantly higher efficacy (54.01% cell death) compared to trastuzumab (26.14%) while sparing PBMCs.
Conclusions:
- HuM6-1B9 shows potential as a novel therapeutic agent for triple-negative breast cancer.
- The study supports further clinical investigation of HuM6-1B9 for TNBC treatment.
- ADCC mediated by HuM6-1B9 represents a promising mechanism for targeting TNBC.
More Related Videos
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
